PDF factsheet
      Z

antiplatelets drug in acute coronary syndrome for all type of patients, clinical trials results

ASA high dose versus ASA low dose
CURRENT - OASIS 7 (ASA), 2010
NCT00335452
High-dose aspirin
versus
Low-dose aspirin
ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization) open
Follow-up duration: 30 days
aspirin versus control
ATACS-pilot, 1990
Aspirin 80mg/d (Heparin + Warfarin)
versus
full-dose heparin followed by warfarin
acute coronary syndromes
Follow-up duration: 3m
aspirin versus placebo
VA-main, 1983
Aspirin 324mg/d
versus
placebo
men with unstable angina double blind
Follow-up duration: 3m
VA-pilot, 0
Aspirin 324 mg/d
versus

Follow-up duration: 3m
RISC, 1990
Aspirin 75mg/d
versus
placebo
men with unstable coronary artery disease (unstable angina or non-Q wave myocardial infarctiondouble blind
Follow-up duration: 12m
Sweden
Canadian (Aspirin vs PBO), 1985
Aspirin 1300mg/d
versus
placebo
patients with unstable angina double blind
Follow-up duration: 18m
ALDUSA-pilot, 0
Aspirin 325mg/d, Aspirin 40mg/d
versus

Follow-up duration: 12m
Théroux, 1988
Aspirin 325 mg twice daily
versus
placebo
acute unstable angina double blind
Follow-up duration: 6d (3m)
aspirin + dipyridamol versus placebo
Prandoni, 1991
Aspirin 50mg/d + Dipyridamol 400mg/d
versus
placebo
patients with acute unstable anginadouble blind
Follow-up duration: 12m
aspirin + sulfinpyrazone versus placebo
Canadian (Aspirin + sulfinpyrazone), 1985
Aspirin 1300mg/d + sulfinpyrazone 800mg/d
versus
placebo
patients with unstable angina double blind
Follow-up duration: 18m
atopaxar versus placebo
LANCELOT ACS,
400-mg loading dose of atopaxar followed by a daily dose of 50 mg, 100 mg, or 200 mg for 12 weeks
versus
placebo
unstable-angina or non-STEMI patients
J-LANCELOT, 2010
atopaxar at a loading dose of 400 mg followed by 50 mg per day, 100 mg per day, or 200 mg per day for 12 weeks
versus
atopaxar at a loading dose of 400 mg followed by placebo
patients with acute coronary syndrome (unstable angina and NSTEMI)
Japan
clopidogrel + aspirin versus aspirin
CURE, 2001
clopidogrel 300 mg immediately, followed by 75 mg once daily + aspirin for 3 to 12 months
versus
aspirin (+placebo)
acute coronary syndromes without ST-segment elevation within 24 hours after the onset of symptomsdouble blind
Follow-up duration: NA (median <9 months)
28 countries
clopidogrel high-dose regimen versus clopidogrel standard-dose
CURRENT OASIS 7 (clopidogrel), 2010
NCT00335452
Double-dose clopidogrel
versus
Standard-dose clopidogrel
ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization)open
Follow-up duration: 30 days
prasugrel versus clopidogrel
TRILOGY ACS (overall population), 2012
NCT00699998
prasugrel 10 mg daily
versus
clopidogrel 75 mg daily
patients with acute coronary syndromes selected for a final treatment strategy of medical management without revascularization within 10 days after the index eventdouble-blind
Follow-up duration: 17 months (median)
52 countries
TRITON-TIMI 38, 2007
NCT00097591
prasugrel 60-mg loading dose and 10-mg daily maintenance dose, for 6 to 15 months
versus
clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months
patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary interventiondouble blind
30 countries
sulfinpyrazone versus placebo
Canadian (sulfinpyrazone alone), 1985
sulfinpyrazone 800mg/d
versus
placebo
patients with unstable angina double blind
Follow-up duration: 18m
ticagrelor versus clopidogrel
PLATO, 2009
NCT00391872
ticagrelor 90mg twice daily
versus
clopidogrel 75mg once daily
patients with an acute coronary syndrome, with or without ST-segment elevation (onset of symptoms within the previous 24h). double blind
Follow-up duration: 1 y
43 countries
DISPERSE-2 (90mg), 2007
ticagrelor 90 mg twice daily
versus
clopidogrel
patients with NSTE-ACS, treated with aspirin and standard therapy for ACSdouble blind
Follow-up duration: 12 weeks
ticlopidine versus control
STAI, 1990
ticlopidine 250 mg b.i.d
versus
untreated control
patients with unstable angina <=48hrs from the pain onsetsingle blind
Follow-up duration: 6m
ticlopidine versus placebo
Florida UA, 0
Ticlopidine 500mg/d
versus

Follow-up duration: 14d
trapidil versus placebo
Modena, 0
trapidil
versus

Follow-up duration: 6m
triflusal versus placebo
Plaza, 1993
triflusal 300 mg three times daily
versus
placebo
patients with unstable anginadouble blind
Follow-up duration: 6m
Spain
vorapaxar versus placebo (on top standard therapy)
TRACER, 2011
NCT00527943
vorapaxar (SCH 530348) oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
versus
Placebo (added to the existing standard of care (eg, aspirin, clopidogrel)
patients with acute coronary syndromedouble-blind

  Options


in first

in second

  Filter